What type of drug is Kymriah (tisagenlecleucel)?
Medically reviewed by Drugs.com. Last updated on Sep 30, 2020.
Kymriah (tisagenlecleucel) is a chimeric antigen receptor T cell (CAR-T) therapy.
It is used in pediatric and young adult patients (up to age 25) with relapsed or refractory (r/r) B-cell acute lymphoblastic leukemia (ALL).
Kymriah is a genetically-modified autologous T-cell immunotherapy. The therapy is derived from a patient's own white blood cells through a process known as leukapheresis.
The white cells are modified genetically to include a new gene that contains a specific protein (a chimeric antigen receptor or CAR) that directs the T-cells to target and kill leukemia cells that have a specific antigen (CD19) on the surface.
Once the cells are modified, they are infused back into the patient to kill the cancer cells. Kymriah is the first FDA-approved cell-based gene therapy in the U.S. See also: https://www.drugs.com/slideshow/car-t-cell-therapy-top-10-questions-answered-1288#slide-1
Related Medical Questions
- What is the cost of Kymriah?
- How is Kymriah administered?
- What is the lifetime or cumulative dose for Adriamycin?
- Is Sprycel a chemotherapy drug?
- Gleevec vs Sprycel vs Tasigna - how do they compare?
- What to avoid when taking Gleevec?
- How much does Blincyto (blinatumomab) cost?
- How long does it take Sprycel (dasatinib) to start working?
- How does Gleevec (imatinib) work?
- Is Tasigna a form of chemotherapy?
- Is there a generic for Gleevec?
- Is Blincyto (blinatumomab) chemotherapy?
- How does Asparlas (calaspargase pegol-mknl) compare to Oncaspar (pegaspargase)?
- How is Blincyto taken / administered?
- Can I take Gleevec while pregnant?